Mirvetuximab soravtansine

Ocular Toxicity:

ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis

MONITORING RECOMMENDATIONS RELATED TO BLACK BOX DATA

• Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated
• Administer prophylactic artificial tears and ophthalmic topical steroids
• Withhold ELAHERE for ocular toxicities until improvement and resume at the same or reduced dose.
• Discontinue ELAHERE for Grade 4 ocular toxicities.

Medication Guides

Elahere

Package Inserts

Elahere